Intravenous Iron Drugs Market To Reach $5.62 Billion By 2030

Intravenous Iron Drugs Market Growth & Trends

The global intravenous iron drugs market size is expected to reach USD 5.62 billion by 2030, expanding at a CAGR of 9.2% from 2024 to 2030, according to a new report by Grand View Research, Inc. Industry rivalry is expected to remain at a higher level over the forecast period. The market is dominated by global players accounting for most of the revenue share. Moreover, growing opportunities attract new players, which further augments the competitive rivalry. The market is fragmented and major players are involved in adopting extensive growth strategies such as entering strategic alliances, acquisitions, and new drug launches to capture a larger share.

The high disease burden of infectious diseases, coupled with poor nutrition, is one of the major causes of anemia among children in this region. The novel coronavirus pandemic has also increased anemia in severely affected patients, causing hypoxia in some cases. This has further increased the demand for intravenous iron drugs for the treatment of anemia across the globe.

The increase in the prevalence of anemia can also be attributed to various gynecological and gastrointestinal disorders, facilitating an increasing uptake of IV treatment globally. For instance, the overall prevalence of anemia is 29.6% in nonpregnant women and 36.5% in pregnant women of the same age group. With growing healthcare budgets and increasing investment, the market is anticipated to grow significantly during the forecast period.

Drawbacks of oral iron drugs such as digestive problems such as stomach aches, constipation, loss of appetite, nausea, and vomiting are reasons for patients to prefer intravenous drugs. The use of intravenous iron drugs has been shown to bring about increased iron adoption by the body, facilitating Erythropoiesis-stimulating Agents (ESAs) to function in an enhanced manner to improve the anemic condition. Other advantages are the preservation of heart health and the ability to be used by dialysis patients, especially those undergoing hemodialysis.

 Request a free sample copy or view report summary: Intravenous Iron Drugs Market Report

Intravenous Iron Drugs Market Report Highlights

• Ferric carboxymaltose dominated the intravenous iron drugs industry in 2023 due to its increasing application, superior performance coupled with fewer adverse effects, and reduced cost

• Iron sucrose held a significant share of the market in 2023. A low rate of severe allergic reactions has increased the adoption rate of these drugs

• The chronic kidney disease segment held the largest share in 2023, due to the increasing prevalence of CKD and CKD-associated iron deficiency anemia cases

• North America held the largest regional share in 2023 due to the high demand for intravenous drugs and the increasing prevalence of GI disorders, cancer, and CKD

• Asia Pacific is estimated to exhibit the fastest growth over the forecast period attributed to growing unmet patient needs, increasing healthcare expenditure, and the local presence of established global players

• Key players include AbbVie Inc.; AMAG Pharmaceuticals (Covis Pharma); Daiichi Sankyo Company, Ltd.; Sanofi; Vifor Pharma Management Ltd. (CSL); PHARMACOSMOS A/S; Zydus Group

Intravenous Iron Drugs Market Segmentation

Grand View Research has segmented the global intravenous iron drugs market based on product, application,and region:

Intravenous Iron Drugs Product Outlook (Revenue, USD Million, 2018 - 2030)

• Iron Dextran

• Iron Sucrose

• Ferric Carboxymaltose

• Others

Intravenous Iron Drugs Application Outlook (Revenue, USD Million, 2018 - 2030)

• Chronic Kidney Disease

• Inflammatory Bowel Disease

• Cancer

• Other Diseases

Intravenous Iron Drugs Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

  • U.S.

  • Canada

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • Japan

  • China

  • India

  • South Korea

  • Australia

  • Thailand

• Latin America

  • Brazil

  • Mexico

  • Argentina

• Middle East & Africa

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players in Intravenous Iron Drugs Market

• AbbVie Inc.

• AMAG Pharmaceuticals (Covis Pharma)

• Daiichi Sankyo Company, Ltd.

• Sanofi

• Vifor Pharma Management Ltd. (CSL)

• PHARMACOSMOS A/S

• Zydus Group

• Rockwell Medical, Inc.